Drugs / Candin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03953196 | Apr → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01653249 | Aug 2012 → Jul 2015 | human papilloma virus infection | University of Arkansas | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02393417 | Mar 2015 → Jan 2018 | common wart | Nielsen BioSciences, Inc. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05889845 | Jan → Aug 2025 | common wart | Nielsen BioSciences, Inc. | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT05216510 Background | Jan → Sep 2022 | type IV hypersensitivity disease | Tonix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05952934 Comparator | Feb 2024 → Jul 2032 expected | head and neck squamous cell carcinoma | University of Arkansas | Recruiting | No outcome recorded |
| Phase 2 | NCT02481414 Comparator | Nov 2015 → Sep 2022 | cervical intraepithelial neoplasia | University of Arkansas | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Nielsen BioSciences, Inc. | Results Nielsen BioSciences Announces Positive Phase 3 Trial Results of CANDIN for the Treatment and Clearance of Common Warts nielsenbio.com ↗
The study successfully met its primary endpoint of the complete resolution of the treated wart without recurrence through 12 weeks post-injection. |
| 2019-03-02 | Nielsen BioSciences, Inc. | Results Phase II clinical trial results presented at the American Academy of Dermatology 2019 Annual Meeting nielsenbio.com ↗
Dr. Stacy R. Smith presented an abstract entitled – “Successful Treatment of Common Warts with Candida Extract – a Phase II study” at the Annual Meeting of the American Academy of Dermatology in Washington DC. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Nielsen BioSciences, Inc. | Nielsen BioSciences Announces Positive Phase 3 Trial Results of CANDIN for the Treatment and Clearance of Common Warts nielsenbio.com ↗ |
| 2025-10-23 | Nielsen BioSciences, Inc. | Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd. nielsenbio.com ↗ |
| 2024-03-05 | Nielsen BioSciences, Inc. | Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts nielsenbio.com ↗ |
| 2019-03-02 | Nielsen BioSciences, Inc. | Phase II clinical trial results presented at the American Academy of Dermatology 2019 Annual Meeting nielsenbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candin | “Subjects will also receive one intradermal injection (0.1 mL) of a positive control (CANDIN®), and one intradermal injection (0.1 mL) of a negative control "diluent".” NCT05216510 ↗8“This study assessed three dosing schemes using Candin®, a standardized purified Candida antigen (PCA), for the treatment of common warts.” PMID 40155509 ↗ Mar 2025 |
| Modality | Other / unclassified | “yeast extract called Candin®” NCT01653249 ↗ |
| Route | Other | “CANDIN administered intralesionally” NCT02393417 ↗ |